Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma

Scientific Reports
Ma YanZhu Jiayong

Abstract

In our previous study, a liver-targeting peptide CSP I-plus modified recombinant human Endostatin (rEndostatin, endostar) (rES-CSP) was constructed and showed potent antiangiogenic capability and could specifically bind to human hepatocellular carcinoma cells to make a direct inhibition in vitro. In this study, the biological activities of rES-CSP in vivo were evaluated by subcutaneous and orthotopic xenograft nude mice model of human hepatocellular carcinoma cells HepG2. We found that rES-CSP significantly decreased tumor volume to 54.9% in the nude mice with subcutaneous xenograft compared with the control. In orthotopic xenograft model, rES-CSP not only decreased tumor volume (to 39.6% compared with the control) and tumor weight, it also increased its biodistribution in the liver tissue and hepatoma tissue. Moreover, lower microvessel density (MVD) and higher apoptotic index (AI) were also observed in the tumor tissues. It had no significant side-effects on the heart, liver, spleen, lung and kidney of mice. Results indicated CSP I-plus modified Endostar may be a potential candidate for a targeting therapy on hepatocellular carcinoma.

References

Jan 1, 1991·Annals of the New York Academy of Sciences·T R ShockleyM L Yarmush
Oct 2, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Amin HajitouAgnès Noël
Aug 10, 2004·International Journal of Cancer. Journal International Du Cancer·Yumi Yokoyama, S Ramakrishnan
Feb 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Malin SundRaghu Kalluri
Jun 29, 2007·International Journal of Cancer. Journal International Du Cancer·Yumi Yokoyama, S Ramakrishnan
Oct 13, 2007·Journal of Pharmaceutical Sciences·Richard T RobertsonKenneth J Longmuir
Mar 19, 2008·Molecular Cancer Therapeutics·Albert LoHan-Chung Wu
Jun 17, 2009·Biotechnology and Applied Biochemistry·Li-Ping JiangYali Chen
Jul 28, 2009·The Journal of Biological Chemistry·Matthew L PlassmeyerDavid L Narum
Aug 12, 2009·International Journal of Pharmaceutics·Kenneth J LongmuirRichard T Robertson
Mar 23, 2010·Transplantation Proceedings·E Varo Pérez, J F Castroagudín
Feb 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abhishek GoyalAbby B Siegel
Sep 6, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Andreas AndreouUNKNOWN International Cooperative Study Group on Hepatocellular Carcinoma
Aug 28, 2014·Journal of Cancer Research and Clinical Oncology·P FitzmorrisA K Singal
Nov 26, 2014·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Zhangjun ChengFeng Shen
Oct 30, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiaochen ChenXinchen Sun
Jan 17, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Xue ZhangHongqi Zhang
Apr 6, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Karen FoguerMaria Helena Bellini

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
ELISA
phage display
xenografts
fluorescence microscopy

Software Mentioned

Image
ANOVE
Pro Plus
Endostar
SPSS13

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.